薬局薬剤師によるがん薬物療法に関する服薬情報等提供書の送付に係わる要因

書誌事項

タイトル別名
  • Factors Related to Submission of Tracing Reports Regarding Cancer Chemotherapy by Pharmacy Pharmacists
  • ヤッキョク ヤクザイシ ニ ヨル ガン ヤクブツ リョウホウ ニ カンスル フクヤク ジョウホウ トウ テイキョウショ ノ ソウフ ニ カカワル ヨウイン

この論文をさがす

抄録

<p>In Japan, use of a report for providing information from pharmacies to medical institutions called as “tracing report (TR)” is not widespread especially in the field of cancer chemotherapy. Identification of the factors related to submission of TRs could enhance the necessity of TRs. The purpose of this study is to clarify the factors related to submission of TRs regarding cancer chemotherapy through a questionnaire survey. A questionnaire survey was conducted at the live web-based seminar regarding cancer chemotherapy held for pharmacists in January 2023. After the questionnaire survey, the participants were divided into those who had submitted at least one TR regarding cancer chemotherapy within one month before the seminar (TR group) and those who had not (non-TR group). The multivariate analysis was conducted to identify factors related to submission of TRs regarding cancer chemotherapy. Of 118 participants, the responses from 93 pharmacy pharmacists involved in dispensing drugs who agreed to participate in this study and fulfilled all questionnaire were analyzed. TR group included 21 participants and non-TR group included 72. As a result of multivariate analysis, “Years of experience in counseling and following-up with patients undergoing cancer chemotherapy (odds ratio: 4.81, p=0.02)” and “Types of workplaces (odds ratio: 3.79, p=0.02)” significantly increased the incidence of submission of TRs regarding cancer chemotherapy. It was revealed that experience of intervention in cancer chemotherapy cases and an environment in which prescriptions for cancer chemotherapy can be handled on a daily basis are important for submission of TRs regarding cancer chemotherapy.</p>

収録刊行物

  • 薬学雑誌

    薬学雑誌 144 (1), 143-150, 2024-01-01

    公益社団法人 日本薬学会

参考文献 (5)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ